SETUP__:
  prototype: A
AA:
  a: Study MET01
  b: MET01
  c: |
    A randomized, single ascending dose, Phase I trial to assess the safety,
    tolerability, and \gls{PK} of once daily oral doses of \drugx\ in healthy adults.
  d: '1'
  e: Randomized, single ascending dose study
  f: Healthy
  g: 30 (5 per DG)
  h: Single dose
  i: 5, 10, 25, 100, 150, 200 mg
  j: 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 20, 24, 48, 72, and 96 hours post-dose
  k: '15'
  l: TBD
A:
  Study: Study MET01
  fileEx: MET01
  Title: |
    A randomized, single ascending dose, Phase I trial to assess the safety,
    tolerability, and \gls{PK} of once daily oral doses of \drugx\ in healthy adults.
  Phase: '1'
  Short: Randomized, single ascending dose study
  Patients: Healthy
  nSub: 30 (5 per DG)
  nDose: Single dose
  D_levels: 5, 10, 25, 100, 150, 200 mg
  obTime: 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 20, 24, 48, 72, and 96 hours post-dose
  nTime: '15'
  Conc: TBD
B:
  Study: Study MET02
  fileEx: MET02
  Title: |
    A randomized, multiple ascending dose, Phase I trial to assess the safety,
    tolerability, and \gls{PK} of \drugx\ in healthy adults.
  Phase: '1'
  Short: Randomized, multiple ascending dose study
  Patients: Healthy
  nSub: 50 (10 per DG)
  nDose: Multiple doses (BID for 6 days)
  D_levels: 10, 25, 50, 75, and 100 mg
  obTime: |
    Post-first dose: 1, 1.5, 2, 4, 6, 8, 12 (pre-dose) hours.
    Pre-third dose: A trough at 24 hours (pre-dose).
    Post-dose: Samples were taken approx. 2 hours post-dose (+/- 1.5 hours).
    for doses at 48, 72, 96, and 120 hours.
    Post-last dose: 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 60, and 84 hours post-dose.
  nTime: '24'
  Conc: TBD
C:
  Study: Study MET03
  fileEx: MET03
  Title: |
    A randomized, multiple dose, Phase I trial to assess the impact of renal
    impairment on the safety, tolerability, and \gls{PK} of \drugx.
  Phase: '1'
  Short: Randomized, multiple dose study
  Patients: |
    Normal ($\geq$90 mL/min), Mild (60-89 mL/min), Moderate (30-59 mL/min), and
    Severe impairment (15-29 mL/min))
  nSub: 40 (10 renal function group)
  nDose: Multiple doses (BID for 6 days)
  D_levels: 25 mg
  obTime: |
    Post-first dose: 1, 1.5, 2, 4, 6, 8, and 12 (pre-dose) hours.
    Pre-third dose: A trough at 24 hours (pre-dose).
    Post-dose: Samples were taken approx. 2 hours post-dose (+/- 1.5 hours) for doses
    at 48, 72, 96, and 120 hours.
    Post-last dose: 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 60, and 84 hours post-dose.
  nTime: '24'
  Conc: TBD
D:
  Study: Study MET04
  fileEx: MET04
  Title: |
    A randomized,  single dose, Phase I trial to assess the impact of hepatic
    impairment on the safety, tolerability, and \gls{PK} of \drugx.
  Phase: '1'
  Short: Randomized,  single dose
  Patients: |
    Normal, Child-Pugh Class A (mild),
    Child-Pugh Class B (moderate), and
    Child-Pugh Class C (severe)
  nSub: 40 (10 per hepatic function group)
  nDose: Single dose
  D_levels: 25 mg
  obTime: |
    1, 1.5, 2, 4, 6, 8, 12, 24, 36, 48, 60, 72, 84, 96, and 120 hours post-dose
  nTime: '15'
  Conc: TBD
